Unlocking Q3 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics

Wall Street analysts expect PTC Therapeutics (PTCT) to post quarterly loss of $1.54 per share in its upcoming report, which indicates a year-over-year increase of 12.5%. Revenues are expected to be$ 173.51 million, down 11.7% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 2.2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this t ...